| Name | Title | Contact Details |
|---|
Etowah Landing is a post-acute care facility that provides a custom-tailored, medically driven rehabilitation program for fast recovery.
To be the Best Community Healthcare System in New England. About Rutland Regional Medical Center The biggest community hospital in Vermont and the second largest hospital in the state, Rutland Regional Medical Center has been providing high quality healthcare to the Rutland Region for more than 100 years. As the needs of our community have grown and changed, so has Rutland Regional, adding services, staff and facilities. Today, Rutland Regional Medical Center is a 144 bed hospital, employing over 1,600 professional and support staff including 227 providers trained in 36 specialty areas. Providing preventive, diagnostic, acute and rehabilitative services, Rutland Regional Medical Center serves Rutland County, portions of southern and central Vermont and communities in eastern New York State. The hospital`s medical staff is supported by excellent nurses, high quality diagnostic and ancillary services and a broad array of sophisticated equipment technology, including advanced diagnostic imaging, a top-of-the-line linear accelerator used in the treatment of cancer patients, and a diagnostic Cardiovascular and Angiographic Lab. At Rutland Regional we manage and adapt to change and growth while continuing our focus on a high standard of personalized, quality medical care, adding key specialties to serve community needs, and focusing on attracting and recruiting highly trained doctors, nurses and staff. We are committed to providing the services, both in and out of the hospital, required to maintain the health of not just our patients, but the entire community
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Oregon Acupuncture Association is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Proper is the modern approach to better sleep - evidence-based, personalized, and holistic, offering premium PhD-designed natural sleep supplements & expert sleep coaching.